Nuclear Medicine Market - Global Trends & Forecast to 2017
The global nuclear medicines market is a fragmented market with the top 5 players holding 47% of the total market share. Cardinal Healthcare contributed the maximum share to the market. The company operates multiple cyclotron facilities and nuclear pharmacies to develop and distribute radiopharmaceuticals. Cardinal Health also focused on collaborations and agreements with universities and small manufacturing firms to enhance its footprint. Other notable players include Covidien, IBA Group, Lantheus Medical Imaging, Nordion, Triad Isotopes, Siemens Healthcare (PETNET Solutions), and NTP Radioisotopes. SPECT radioisotopes contributed the highest amount of revenue to the nuclear medicines market and hence players associated with SPECT radioisotopes, especially those in Tc-99m production, secured leading positions in the market. Besides the gigantic Tc-99m market, the PET radioisotopes market was dominated by F-18 isotopes whereas I-131 gained maximum popularity in the beta therapy market segment.
The trend of using cyclotrons and alternative production methods of Tc-99m production offers vast opportunities for new market entrants, resulting in increased competition since many local players are expected to capitalize on domestic opportunities.
Two major market strategies were adopted in the global nuclear medicines market by generator manufacturers and radiopharmaceutical processors. In the processors market, shifting of the operational model towards LEU (Low Enriched Uranium) from HEU (High Enriched Uranium) for Mo-99 production was a major trend. Covidien, Nordion, and NTP Radioisotopes Pty. Ltd. were pioneers to establish this adoption. On the other hand, ensuring a sustainable supply chain was the prime aim of generator manufacturers since limited half-life is a major concern in radioisotopes distribution. IBA Group, Lantheus, Covidien, NTP Radioisotopes, and FujiFilm were the key companies to follow this trend.
Acquisitions and mergers, new product developments, agreements and collaborations, and expansions were the main developments followed by the key players in the global nuclear medicine market. Agreements and collaborations accounted for the maximum share (40%) amongst all market strategies in 2012. The major players that followed this strategy in 2012 were Lantheus Medical Imaging, Inc. (U.S.), Cardinal Health, Inc. (U.S.), and Nordion, Inc. (Canada). Besides these developments, approval of future radiopharmaceuticals gave a new dimension to this market. Notable approvals included the Fludeoxyglucose F-18 Injection of Siemens PETNET Solutions, DaTscan (Ioflupane I-123 Injection) of GE Healthcare, and DEFINITY (Perflutren Lipid Microsphere) Injectable Suspension of Lantheus Medical Imaging.
Despite the competitive pressure by local players, key contributors are still expected to retain their leading positions in the global nuclear medicines market. This is primarily supported by their forward and backward integrations and ongoing clinical studies to pave the way for market development.
Related Reports
Nuclear Medicine Market & Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to 2017
Contact:
Mr. Rohan
North - Dominion Plaza,
17304,Preston Road,
Suite 800, Dallas, TX 75252
Tel: +1-888-600-6441
Email: [email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
